GlaxoSmithKline Improves Efficiencies in Their Sourcing Strategy Using Wipro's ''Factory Model''

BANGALORE, India--()--Oct. 25, 2005--Wipro Technologies, the global IT services division of Wipro Limited (NYSE:WIT), today announced that its innovative delivery methodology called the "Factory Model" has helped its client GlaxoSmithKline (NYSE:GSK) (LSE:GSK) improve their sourcing efficiencies through strategic offshore factories initiatives. Wipro has been a strategic partner to GlaxoSmithKline and has been consistently delivering IT solutions that add business value to GlaxoSmithKline.

The "Factory Model" enables organizations manage globally distributed functions or services efficiently, through combination of virtual shared services organization, process standardization and re-use. It also enables leveraging specialized knowledge and learning gained from architecting solutions for a few business functions and applying it across the enterprise. The "Factory Model" has evolved from Wipro's Innovation council and called so because of its resemblance to the manufacturing assembly line where efficiencies and quality improvements are driven through standardization of processes.

Commenting on benefits of Wipro's factory model, Ingo Elfering Vice President -- Global Application Services, GlaxoSmithKline says, "The Factory Model highlights Wipro's commitment to excellence and its ability to innovate and add value to its customers. The model has demonstrated success through a number of small to medium size projects through this model very quickly thereby accelerating the overall offshore strategy implementation at GlaxoSmithKline. Factory Model greatly reduces the amount of process overhead and non value-adding work in offshoring and is set to change our outsourcing strategy in a significant manner. Based on the success of this model last year, this model is being replicated across GSK for a number of other IT streams going forward."

NS Bala, Vice President -- Manufacturing solutions, Wipro Technologies said, "GlaxoSmithKline's endeavor towards standardization of its IT systems through aggregation of discrete global projects is a strategically important decision which will help them reap the benefits of economies of scale and accelerated pace of offshoring. We are confident that their choice of Wipro's 'Factory Model' will help them achieve their goal of optimizing their sourcing strategy."

"While Factory Model is gaining widespread interest from our customer/prospect base, we see particular interest from pharmaceutical organizations. Given their global spread and growth through mergers and acquisitions we find the factory model generating greater interest for its potential to drive cost savings and standardization at the same time," mentions Vijayanand Vadrevu, General Manager for Pharma solutions, Wipro Technologies.

About Wipro Limited

Wipro Limited is the first PCMM Level 5 and SEI CMM Level 5 certified IT Services Company globally. Wipro provides comprehensive IT solutions and services, including systems integration, information systems outsourcing, package implementation, software application development and maintenance, and research and development services to corporations globally. In the Indian market, Wipro is a leader in providing IT solutions and services for the corporate segment in India offering system integration, network integration, software solutions and IT services. Wipro also has profitable presence in niche market segments of consumer products and lighting. In the Asia Pacific and Middle East markets, Wipro provides IT solutions and services for global corporations. Wipro's ADSs are listed on the New York Stock Exchange, and its equity shares are listed in India on the Stock Exchange -- Mumbai and the National Stock Exchange, among others.

About GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) (LSE:GSK) -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

Forward-looking & cautionary statements

Certain statements in this release concerning our future growth prospects and our ability to successfully complete and integrate potential acquisitions are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding our ability to integrate and manage acquired IT professionals, our ability to integrate acquired assets in a cost effective and timely manner, fluctuations in earnings, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, liability for damages on our service contracts, the success of the companies in which Wipro has made strategic investments, withdrawal of fiscal governmental incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission. These filings are available at www.sec.gov. Wipro may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. Wipro does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

For further information, please visit our websites at www.wipro.com, www.wiprocorporate.com & www.wipro.co.in .

Contacts

Wipro Technologies
Aravind Sadaiappan, +91-80-28520408
Aravind.sadaiappan@wipro.com

Contacts

Wipro Technologies
Aravind Sadaiappan, +91-80-28520408
Aravind.sadaiappan@wipro.com